Geller Biopharm, Inc. v. Amunix Pharmaceuticals, Inc.
- John Cronan
- 1:20-cv-04334
- U.S. District Court · Southern District of New York
- 2
In Geller Biopharm v. Amunix, Judge Cronan granted Amunix’s request to file reply-brief portions referring to the FSA under seal.
Amunix Pharmaceuticals, Inc. and Geller Biopharm, Inc.; the ruling governs public access to specified portions of Amunix’s reply brief.
What happened
Geller Biopharm, Inc. v. Amunix Pharmaceuticals, Inc. concerns Amunix’s request to keep parts of its reply brief confidential.
Amunix sought to seal portions that quoted or described sensitive terms of the Second FSA. The request followed an earlier order allowing the Second FSA and descriptions of its terms to be filed under seal; Geller Biopharm consented.
Judge John P. Cronan granted Amunix’s request to file under seal the portions of its reply referring to the FSA.
The detailed version
- Geller Biopharm, Inc. v. Amunix Pharmaceuticals, Inc. · No. 1:20-cv-04334
- John Cronan
- Nov. 17, 2020
Background
Amunix Pharmaceuticals, Inc. asked the court for permission to file under seal portions of its reply brief supporting its motion to dismiss. Those portions described or directly quoted confidential and sensitive terms of the Second FSA. Amunix said the request was consistent with an earlier order allowing the Second FSA and descriptions of its terms to be filed under seal. The earlier order found that the competitive harm from disclosure outweighed the general presumption that court records should be public and that the proposed redactions were appropriately limited. Geller Biopharm, Inc.’s counsel consented to the request.
Ruling
The court granted Amunix’s request to file under seal the portions of its reply referring to the FSA. The provided text does not address the merits of Amunix’s motion to dismiss.
Disposition
The request to file the specified reply-brief portions under seal was granted.
Read the full 2-page opinion on CourtListener, the free public archive maintained by the Free Law Project.